基于“肠-肾”轴理论的肠道微生态影响慢性肾病发生发展的机制及干预治疗

朱金惠; 王玲; 陶金华; 马振祥; 段金廒; 刘培; 江曙

doi:10.14148/j.issn.1672-0482.2023.1054

基于“肠-肾”轴理论的肠道微生态影响慢性肾病发生发展的机制及干预治疗

doi: 10.14148/j.issn.1672-0482.2023.1054

朱金惠^{1, 2,},
王玲²,
陶金华^{1, 2, 3, ,},
马振祥¹,
段金廒³,
刘培³,
江曙³

1.
南通大学公共卫生学院, 江苏南通 226001
2.
南通大学药学院, 江苏南通 226019
3.
南京中医药大学中药资源协同创新研究中心, 江苏南京 210023

基金项目:

国家自然科学基金面上项目 81974518

江苏省高校自然科学基金面上项目 19KJB360019

江苏省大学生创新科研项目 202110304104Y

研究生创新科研项目 KYCX21_3132

详细信息

作者简介:
朱金惠, 硕士研究生, E-mail: 2980728440@qq.com

通讯作者:
陶金华, 女，高级实验师, 主要从事胃肠道微生物与中药相互作用及机制研究, E-mail: taojinhua2000@ntu.edu.cn

中图分类号: R285.5
计量
- 文章访问数: 281
- HTML全文浏览量: 31
- PDF下载量: 30
- 被引次数: 0
出版历程
- 收稿日期: 2023-03-14
- 网络出版日期: 2023-11-10
- 发布日期: 2023-10-10

To Discuss the Mechanism and Intervention Treatment of Intestinal Microecology in the Development of Chronic Kidney Disease Based on the Theory of "Gut-Kidney Axis"

ZHU Jin-hui^{1, 2
,},
WANG Ling²,
TAO Jin-hua^{1, 2, 3
, ,},
MA Zhen-xiang¹,
DUAN Jin-ao³,
LIU Pei³,
JIANG Shu³

1.
School of Public Health, Nantong University, Nantong 226001, China
2.
School of Pharmacy, Nantong University, Nantong 226019, China
3.
Collaborative Innovation Center of Chinese Medicine Resources, Nanjing University of Chinese Medicine, Nanjing 210023, China

摘要

摘要: 慢性肾脏疾病(Chronic kidney disease, CKD)是指由各种原因引起的慢性肾脏结构和功能障碍, 包括各种原发的、继发的肾小球肾炎、肾小管损伤和肾血管病变等。复杂的发病机制与特异性治疗方案的缺乏使慢性肾病成为威胁人类生命健康的重大疾病。基于“肠-肾”轴理论, 肠道菌群研究的病因学说为慢性肾病发病机制提供了一个全新的视角。概述了肠道微生态在慢性肾病发生发展过程中所发挥的作用, 以及阐述以肠道菌群为靶点, 中医药或益生菌益生元作为干预途径治疗慢性肾病的研究现状。这些研究将为探索针对肠道微生态的慢性肾病临床治疗新策略, 提供重要的理论依据。
- 慢性肾病 /
- 肠道菌群 /
- 尿毒素 /
- 中医药 /
- 益生元(菌)
Abstract: Chronic kidney disease(CKD) refers to chronic renal structure and dysfunction caused by various causes, including various primary and secondary glomerulonephritis, renal tubular injury and renal vascular lesions. The complex mechanisms and the lack of specific treatment make the disease become a major problem threatening human life and health. Based on the "gut-kidney axis" theory, etiology of intestinal flora studies provide a new perspective for the study of the mechanisms. In this review, we discuss the role of intestinal microecology in the CKD, summarize the research status of treating CKD with intestinal flora as target and traditional chinese medicine or prebiotics (probiotics) as intervention approaches. These studies provide an important theoretical basis for new treatment strategies of chronic kidney disease.
- chronic kidney disease /
- intestinal flora /
- uremic toxins /
- traditional Chinese medicine /
- prebiotics (probiotics)

HTML全文

图 1 肠道微生态与CKD及其炎症信号关联示意图

Figure 1. Schematic diagram of the correlation between gut microbiota and CKD and its inflammatory signals

下载: 全尺寸图片幻灯片

参考文献(84)

[1]	WEBSTER AC, NAGLER EV, MORTON RL, et al. Chronic kidney disease[J]. Lancet, 2017, 389(10075): 1238-1252. doi: 10.1016/S0140-6736(16)32064-5
[2]	杨一歌, 李鹤, 张秀立, 等. 慢性肾病及相关并发症治疗药物研究进展[J]. 药学学报, 2022, 57(9): 2682-2695. https://www.cnki.com.cn/Article/CJFDTOTAL-YXXB202209012.htm YANG YG, LI H, ZHANG XL, et al. Progress on research and development of drug for chronic kidney disease and related comorbidities[J]. Acta Pharm Sin, 2022, 57(9): 2682-2695. https://www.cnki.com.cn/Article/CJFDTOTAL-YXXB202209012.htm
[3]	WANG ZW, ZHANG C. From AKI to CKD: Maladaptive repair and the underlying mechanisms[J]. Int J Mol Sci, 2022, 23(18): 10880. doi: 10.3390/ijms231810880
[4]	FRAK W, KUCMIERZ J, SZLAGOR M, et al. New insights into molecular mechanisms of chronic kidney disease[J]. Biomedicines, 2022, 10(11): 2846. doi: 10.3390/biomedicines10112846
[5]	王仡豪, 郁胜强. 慢性肾脏病与肠道微生态的相互影响[J]. 临床肾脏病杂志, 2019, 19(9): 700-705. https://www.cnki.com.cn/Article/CJFDTOTAL-LCSB201909013.htm WANG YH, YU SQ. Interaction between chronic kidney disease and intestinal microbiome[J]. J Clin Nephrol, 2019, 19(9): 700-705. https://www.cnki.com.cn/Article/CJFDTOTAL-LCSB201909013.htm
[6]	全晶晶, 黄志军. 基于肠道菌群的慢性肾病药物治疗研究现状[J]. 中国临床药理学杂志, 2021, 37(21): 2985-2988. https://www.cnki.com.cn/Article/CJFDTOTAL-GLYZ202121029.htm QUAN JJ, HUANG ZJ. Research progress of drug therapy for chronic kidney disease based on intestinal flora[J]. Chin J Clin Pharmacol, 2021, 37(21): 2985-2988. https://www.cnki.com.cn/Article/CJFDTOTAL-GLYZ202121029.htm
[7]	WILKINS LJ, MONGA M, MILLER AW. Defining dysbiosis for a cluster of chronic diseases[J]. Sci Rep, 2019, 9(1): 12918. doi: 10.1038/s41598-019-49452-y
[8]	李昭君, 陈晓光, 张森. 肠道菌群-代谢物网络同慢性肾病发生发展的关系及其关联机制研究进展[J]. 药学学报, 2020, 55(12): 2777-2784. https://www.cnki.com.cn/Article/CJFDTOTAL-YXXB202012002.htm LI ZJ, CHEN XG, ZHANG S. The role of the intestinal microflora dysbiosis in chronic kidney disease[J]. Acta Pharm Sin, 2020, 55(12): 2777-2784. https://www.cnki.com.cn/Article/CJFDTOTAL-YXXB202012002.htm
[9]	LI FX, WANG MH, WANG JP, et al. Alterations to the gut microbiota and their correlation with inflammatory factors in chronic kidney disease[J]. Front Cell Infect Microbiol, 2019, 9: 206. doi: 10.3389/fcimb.2019.00206
[10]	CHUNG S, BARNES JL, ASTROTH KS. Gastrointestinal microbiota in patients with chronic kidney disease: A systematic review[J]. Adv Nutr, 2019, 10(5): 888-901. doi: 10.1093/advances/nmz028
[11]	BOSSOLA M, SANGUINETTI M, SCRIBANO D, et al. Circulating bacterial-derived DNA fragments and markers of inflammation in chronic hemodialysis patients[J]. Clin J Am Soc Nephrol, 2009, 4(2): 379-385. doi: 10.2215/CJN.03490708
[12]	SHI KH, WANG FQ, JIANG HL, et al. Gut bacterial translocation may aggravate microinflammation in hemodialysis patients[J]. Dig Dis Sci, 2014, 59(9): 2109-2117. doi: 10.1007/s10620-014-3202-7
[13]	KIKUCHI M, UENO M, ITOH Y, et al. Uremic toxin-producing gut microbiota in rats with chronic kidney disease[J]. Nephron, 2017, 135(1): 51-60. doi: 10.1159/000450619
[14]	FENG YL, CAO G, CHEN DQ, et al. Microbiome-metabolomics reveals gut microbiota associated with glycine-conjugated metabolites and polyamine metabolism in chronic kidney disease[J]. Cell Mol Life Sci, 2019, 76(24): 4961-4978. doi: 10.1007/s00018-019-03155-9
[15]	JAZANI NH, SAVOJ J, LUSTGARTEN M, et al. Impact of gut dysbiosis on neurohormonal pathways in chronic kidney disease[J]. Diseases, 2019, 7(1): 21. doi: 10.3390/diseases7010021
[16]	YANG T, RICHARDS EM, PEPINE CJ, et al. The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease[J]. Nat Rev Nephrol, 2018, 14(7): 442-456. doi: 10.1038/s41581-018-0018-2
[17]	MEIJERS B, FARRE R, DEJONGH S, et al. Intestinal barrier function in chronic kidney disease[J]. Toxins, 2018, 10(7): 298. doi: 10.3390/toxins10070298
[18]	MYDLÍK M, DERZSIOVÁ K. Oxalic acid as a uremic toxin[J]. J Ren Nutr, 2008, 18(1): 33-39. doi: 10.1053/j.jrn.2007.10.008
[19]	DURANTON F, COHEN G, DE SMET R, et al. Normal and pathologic concentrations of uremic toxins[J]. J Am Soc Nephrol, 2012, 23(7): 1258-1270. doi: 10.1681/ASN.2011121175
[20]	ALI BH, INUWA I, AL ZA'ABI M, et al. Renal and myocardial histopathology and morphometry in rats with adenine-induced chronic renal failure: Influence of gum acacia[J]. Cell Physiol Biochem, 2014, 34(3): 818-828. doi: 10.1159/000363045
[21]	GRYP T, VANHOLDER R, VANEECHOUTTE M, et al. P-cresyl sulfate[J]. Toxins, 2017, 9(2): 52. doi: 10.3390/toxins9020052
[22]	GOMÓŁKA M, NIEMCZYK L, SZAMOTULSKA K, et al. Protein-bound solute clearance during hemodialysis[J]. Adv Exp Med Biol, 2019, 1153: 69-77.
[23]	李莉, 李静, 袁发焕, 等. 尿毒症毒素对甲酚对人冠状动脉内皮细胞氧化应激的影响[J]. 第三军医大学学报, 2021, 43(16): 1543-1549. https://www.cnki.com.cn/Article/CJFDTOTAL-DSDX202116006.htm LI L, LI J, YUAN FH, et al. Effects of uremic toxin p-cresol on oxidative stress in human coronary artery endothelial cells[J]. J Third Mil Med Univ, 2021, 43(16): 1543-1549. https://www.cnki.com.cn/Article/CJFDTOTAL-DSDX202116006.htm
[24]	WATANABE H, MIYAMOTO Y, HONDA D, et al. P-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase[J]. Kidney Int, 2013, 83(4): 582-592. doi: 10.1038/ki.2012.448
[25]	丁瑜, 王健, 梁新, 等. 尿毒症毒素对甲酚对单核细胞体外释放炎症因子的影响[J]. 解放军医学杂志, 2015, 40(1): 35-39. https://www.cnki.com.cn/Article/CJFDTOTAL-JFJY201501009.htm DING Y, WANG J, LIANG X, et al. An in vitro study of effects of the uremic toxin p-cresol on release of inflammatory cytokines from monocytes[J]. Med J Chin People's Liberation Army, 2015, 40(1): 35-39. https://www.cnki.com.cn/Article/CJFDTOTAL-JFJY201501009.htm
[26]	TANG WH, WANG ZN, KENNEDY DJ, et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease[J]. Circ Res, 2015, 116(3): 448-455. doi: 10.1161/CIRCRESAHA.116.305360
[27]	张青, 刘旭生, 张蕾. 糖尿病肾脏病患者肠道菌群紊乱的发生发展机制[J]. 世界科学技术-中医药现代化, 2020, 22(9): 3235-3240. https://www.cnki.com.cn/Article/CJFDTOTAL-SJKX202009025.htm ZHANG Q, LIU XS, ZHANG L. Pathogenesis of intestinal flora disturbance in patients with diabetic kidney disease[J]. Mod Tradit Chin Med Mater Med World Sci Technol, 2020, 22(9): 3235-3240. https://www.cnki.com.cn/Article/CJFDTOTAL-SJKX202009025.htm
[28]	SELDIN MM, MENG YH, QI HX, et al. Trimethylamine N-oxide promotes vascular inflammation through signaling of mitogen-activated protein kinase and nuclear factor-κB[J]. J Am Heart Assoc, 2016, 5(2): e002767. doi: 10.1161/JAHA.115.002767
[29]	CHEN K, ZHENG XQ, FENG MC, et al. Gut microbiota-dependent metabolite trimethylamine N-oxide contributes to cardiac dysfunction in western diet-induced obese mice[J]. Front Physiol, 2017, 8: 139.
[30]	RAPA SF, PRISCO F, POPOLO A, et al. Pro-inflammatory effects of indoxyl sulfate in mice: Impairment of intestinal homeostasis and immune response[J]. Int J Mol Sci, 2021, 22(3): 1135. doi: 10.3390/ijms22031135
[31]	DOU L, POITEVIN S, SALLéE M, et al. Aryl hydrocarbon receptor is activated in patients and mice with chronic kidney disease[J]. Kidney Int, 2018, 93(4): 986-999. doi: 10.1016/j.kint.2017.11.010
[32]	彭印, 徐雪君, 李建萍, 等. 靶向肠道菌群调控肠源尿毒素代谢通路干预慢性肾病进展的治疗策略分析[J]. 药学学报, 2021, 56(1): 37-49. https://www.cnki.com.cn/Article/CJFDTOTAL-YXXB202101005.htm PENG Y, XU XJ, LI JP, et al. Strategy to delay the progression of chronic kidney disease by targeting gut microbiota and uremic toxins metabolism pathway[J]. Acta Pharm Sin, 2021, 56(1): 37-49. https://www.cnki.com.cn/Article/CJFDTOTAL-YXXB202101005.htm
[33]	BRITO JS, BORGES NA, ANJOS JSD, et al. Aryl hydrocarbon receptor and uremic toxins from the gut microbiota in chronic kidney disease patients: Is there a relationship between them?[J]. Biochemistry, 2019, 58(15): 2054-2060. doi: 10.1021/acs.biochem.8b01305
[34]	LI Y, YAN J, WANG MJ, et al. Uremic toxin indoxyl sulfate promotes proinflammatory macrophage activation by regulation of β-catenin and YAP pathways[J]. J Mol Histol, 2021, 52(2): 197-205. doi: 10.1007/s10735-020-09936-y
[35]	DOU L, SALLEE M, CERINI C, et al. The cardiovascular effect of the uremic solute indole-3 acetic acid[J]. J Am Soc Nephrol, 2015, 26(4): 876-887. doi: 10.1681/ASN.2013121283
[36]	LIABEUF S, VILLAIN C, MASSY ZA. Protein-bound toxins: Has the Cinderella of uraemic toxins turned into a princess?[J]. Clin Sci, 2016, 130(23): 2209-2216. doi: 10.1042/CS20160393
[37]	刘松珍, 张雁, 张名位, 等. 肠道短链脂肪酸产生机制及生理功能的研究进展[J]. 广东农业科学, 2013, 40(11): 99-103. doi: 10.3969/j.issn.1004-874X.2013.11.029 LIU SZ, ZHANG Y, ZHANG MW, et al. Research progress on producing mechanism and physiological functions of intestinal short chain fatty acids[J]. Guangdong Agric Sci, 2013, 40(11): 99-103. doi: 10.3969/j.issn.1004-874X.2013.11.029
[38]	MARINELLI L, MARTIN-GALLAUSIAUX C, BOURHIS JM, et al. Identification of the novel role of butyrate as AhR ligand in human intestinal epithelial cells[J]. Sci Rep, 2019, 9(1): 643. doi: 10.1038/s41598-018-37019-2
[39]	STOCKINGER B, SHAH K, WINCENT E. AHR in the intestinal microenvironment: Safeguarding barrier function[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(8): 559-570. doi: 10.1038/s41575-021-00430-8
[40]	HEANEY LM, DAVIES OG, SELBY NM. Gut microbial metabolites as mediators of renal disease: Do short-chain fatty acids offer some hope?[J]. Future Sci OA, 2019, 5(4): FSO384. doi: 10.4155/fsoa-2019-0013
[41]	JAZANI NH, SAVOJ J, LUSTGARTEN M, et al. Impact of gut dysbiosis on neurohormonal pathways in chronic kidney disease[J]. Diseases, 2019, 7(1): 21. doi: 10.3390/diseases7010021
[42]	谢小慧, 代思源, 戴艳玲, 等. 基于肠-肾轴理论浅析膳食纤维对慢性肾病的影响[J]. 中南大学学报(医学版), 2020, 45(2): 193-197. https://www.cnki.com.cn/Article/CJFDTOTAL-HNYD202002017.htm XIE XH, DAI SY, DAI YL, et al. Influence of dietary fiber on chronic kidney disease: Base on the gut-kidney axis theory[J]. J Cent South Univ Med Sci, 2020, 45(2): 193-197. https://www.cnki.com.cn/Article/CJFDTOTAL-HNYD202002017.htm
[43]	MCINTYRE CW, HARRISON LEA, ELDEHNI MT, et al. Circulating endotoxemia: A novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease[J]. Clin J Am Soc Nephrol, 2011, 6(1): 133-141. doi: 10.2215/CJN.04610510
[44]	ANDERSEN K, KESPER MS, MARSCHNER JA, et al. Intestinal dysbiosis, barrier dysfunction, and bacterial translocation account for CKD-related systemic inflammation[J]. J Am Soc Nephrol, 2017, 28(1): 76-83. doi: 10.1681/ASN.2015111285
[45]	CARPENTER S, O'NEILL LAJ. Recent insights into the structure of Toll-like receptors and post-translational modifications of their associated signalling proteins[J]. Biochem J, 2009, 422(1): 1-10. doi: 10.1042/BJ20090616
[46]	KUZMICH NN, SIVAK KV, CHUBAREV VN, et al. TLR4 signaling pathway modulators as potential therapeutics in inflammation and sepsis[J]. Vaccines, 2017, 5(4): 34. doi: 10.3390/vaccines5040034
[47]	KOPPE L, PELLETIER CC, ALIX PM, et al. Insulin resistance in chronic kidney disease: New lessons from experimental models[J]. Nephrol Dial Transplant, 2014, 29(9): 1666-1674. doi: 10.1093/ndt/gft435
[48]	NAKASHIMA A, KATO K, OHKIDO I, et al. Role and treatment of insulin resistance in patients with chronic kidney disease: A review[J]. Nutrients, 2021, 13(12): 4349. doi: 10.3390/nu13124349
[49]	DE BOER IH, ZELNICK L, AFKARIAN M, et al. Impaired glucose and insulin homeostasis in moderate-severe CKD[J]. J Am Soc Nephrol, 2016, 27(9): 2861-2871. doi: 10.1681/ASN.2015070756
[50]	XU H, HUANG XY, ARNLÖV J, et al. Clinical correlates of insulin sensitivity and its association with mortality among men with CKD stages 3 and 4[J]. Clin J Am Soc Nephrol, 2014, 9(4): 690-697. doi: 10.2215/CJN.05230513
[51]	KOPPE L, NYAM E, VIVOT K, et al. Urea impairs β cell glycolysis and insulin secretion in chronic kidney disease[J]. J Clin Invest, 2016, 126(9): 3598-3612. doi: 10.1172/JCI86181
[52]	MAK RH. Insulin and its role in chronic kidney disease[J]. Pediatr Nephrol, 2008, 23(3): 355-362. doi: 10.1007/s00467-007-0611-2
[53]	HEIANZA Y, SUN D, LI X, et al. Gut microbiota metabolites, amino acid metabolites and improvements in insulin sensitivity and glucose metabolism: The POUNDS Lost trial[J]. Gut, 2019, 68(2): 263-270. doi: 10.1136/gutjnl-2018-316155
[54]	KOPPE L, PILLON NJ, VELLA RE, et al. P-Cresyl sulfate promotes insulin resistance associated with CKD[J]. J Am Soc Nephrol, 2013, 24(1): 88-99. doi: 10.1681/ASN.2012050503
[55]	CARICILLI AM, PICARDI PK, DE ABREU LL, et al. Retraction: Gut microbiota is a key modulator of insulin resistance in TLR 2 knockout mice[J]. PLoS Biol, 2016, 14(5): e1002479. doi: 10.1371/journal.pbio.1002479
[56]	DEPOMMIER C, EVERARD A, DRUART C, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: A proof-of-concept exploratory study[J]. Nat Med, 2019, 25(7): 1096-1103. doi: 10.1038/s41591-019-0495-2
[57]	王勤, 杨亦彬. 肠道菌群失调对糖尿病及糖尿病肾病影响的研究进展[J]. 医学综述, 2019, 25(3): 530-534. doi: 10.3969/j.issn.1006-2084.2019.03.023 WANG Q, YANG YB. Research progress in influence of intestinal flora imbalance on diabetes mellitus and diabetic nephropathy[J]. Med Recapitul, 2019, 25(3): 530-534. doi: 10.3969/j.issn.1006-2084.2019.03.023
[58]	胡文兴, 刘敏. 益生菌对维持性血液透析慢性肾脏病患者肠道菌群失调的影响[J]. 中国微生态学杂志, 2020, 32(11): 1323-1326. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGWS202011018.htm HU WX, LIU M. Effect of probiotics on intestinal flora dysbiosis in patients with chronic kidney disease on maintenance hemodialysis[J]. Chin J Microecol, 2020, 32(11): 1323-1326. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGWS202011018.htm
[59]	RANGANATHAN N, PATEL B, RANGANATHAN P, et al. Probiotic amelioration of azotemia in 5/6th nephrectomized Sprague-Dawley rats[J]. Sci World J, 2005, 5: 652-660. doi: 10.1100/tsw.2005.86
[60]	CASTILLO-RODRIGUEZ E, FERNANDEZ-PRADO R, ESTERAS R, et al. Impact of altered intestinal microbiota on chronic kidney disease progression[J]. Toxins, 2018, 10(7): 300. doi: 10.3390/toxins10070300
[61]	NATARAJAN R, PECHENYAK B, VYAS U, et al. Randomized controlled trial of strain-specific probiotic formulation (Renadyl) in dialysis patients[J]. Biomed Res Int, 2014, 2014: 568571.
[62]	HYUN HS, PAIK KH, CHO HY. P-Cresyl sulfate and indoxyl sulfate in pediatric patients on chronic dialysis[J]. Korean J Pediatr, 2013, 56(4): 159-164. doi: 10.3345/kjp.2013.56.4.159
[63]	FAVERO C, GIORDANO L, MIHAILA SM, et al. Postbiotics and kidney disease[J]. Toxins, 2022, 14(9): 623. doi: 10.3390/toxins14090623
[64]	胡学智. 益生元—双歧杆菌生长促进因子[J]. 工业微生物, 2005, 35(2): 50-60. https://www.cnki.com.cn/Article/CJFDTOTAL-GYWS200502009.htm HU XZ. Prebiotics-Bifidobacterium growth promoting factor[J]. Ind Microbiol, 2005, 35(2): 50-60. https://www.cnki.com.cn/Article/CJFDTOTAL-GYWS200502009.htm
[65]	KIEFFER DA, PICCOLO BD, VAZIRI ND, et al. Resistant starch alters gut microbiome and metabolomic profiles concurrent with amelioration of chronic kidney disease in rats[J]. Am J Physiol Renal Physiol, 2016, 310(9): F857-F871. doi: 10.1152/ajprenal.00513.2015
[66]	ESGALHADO M, KEMP JA, AZEVEDO R, et al. Could resistant starch supplementation improve inflammatory and oxidative stress biomarkers and uremic toxins levels in hemodialysis patients?A pilot randomized controlled trial[J]. Food Funct, 2018, 9(12): 6508-6516. doi: 10.1039/C8FO01876F
[67]	SUEYOSHI M, FUKUNAGA M, MEI M, et al. Effects of lactulose on renal function and gut microbiota in adenine-induced chronic kidney disease rats[J]. Clin Exp Nephrol, 2019, 23(7): 908-919. doi: 10.1007/s10157-019-01727-4
[68]	VALLIANOU NG, MITESH S, GKOGKOU A, et al. Chronic kidney disease and cardiovascular disease: Is there any relationship?[J]. Curr Cardiol Rev, 2019, 15(1): 55-63.
[69]	AGARWAL P, GARG V, KARAGAIAH P, et al. Chronic kidney disease: Associated pruritus[J]. Toxins, 2021, 13(8): 527. doi: 10.3390/toxins13080527
[70]	TU X, LIU F, JORDAN JB, et al. "Huang Qi Elixir" for proteinuria in patients with diabetic nephropathy: A study protocol for a randomized controlled pilot trial[J]. Trials, 2013, 14: 223.
[71]	CAI HD, SU SL, QIAN DW, et al. Renal protective effect and action mechanism of Huangkui capsule and its main five flavonoids[J]. J Ethnopharmacol, 2017, 206: 152-159.
[72]	冯桃花, 刘文康, 武宁, 等. 益肾健脾泻浊中药对慢性肾脏病妊娠大鼠肾脏NLRP3/caspase-1/IL-1β信号通路及细胞焦亡的影响[J]. 世界科学技术-中医药现代化, 2021, 23(2): 451-461. https://www.cnki.com.cn/Article/CJFDTOTAL-SJKX202102018.htm FENG TH, LIU WK, WU N, et al. Effect of Yiqi Jianpi Xiezhuo Decoction on NLRP3/caspase-1/IL-1β signaling pathway and pyroptosis in pregnant rats with chronic kidney disease[J]. Mod Tradit Chin Med Mater Med World Sci Technol, 2021, 23(2): 451-461. https://www.cnki.com.cn/Article/CJFDTOTAL-SJKX202102018.htm
[73]	耿贤华, 彭越, 彭建中. 彭建中教授辨治肾病十八法[J]. 光明中医, 2021, 36(9): 1420-1423. https://www.cnki.com.cn/Article/CJFDTOTAL-GMZY202109019.htm GENG XH, PENG Y, PENG JZ. Professor Peng Jianzhong's eighteen methods of differentiating and treating nephropathy[J]. Guangming J Chin Med, 2021, 36(9): 1420-1423. https://www.cnki.com.cn/Article/CJFDTOTAL-GMZY202109019.htm
[74]	王庆谚, 郑洪新. 中医"肾阴肾阳失常"与肠屏障功能损伤的机制[J]. 中华中医药学刊, 2019, 37(3): 635-637. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYHS201903030.htm WANG QY, ZHENG HX. "kidney Yin and kidney Yang disorder" in traditional Chinese medicine and mechanism of intestinal barrier dysfunction[J]. Chin Arch Tradit Chin Med, 2019, 37(3): 635-637. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYHS201903030.htm
[75]	LIANG Z, HU X, LIN R, et al. Identification of shared gene signatures and molecular mechanisms between chronic kidney disease and ulcerative colitis[J]. Front Immunol, 2023, 14: 1078310.
[76]	MO YN, JIE XN, WANG LX, et al. Bupi Yishen formula attenuates kidney injury in 5/6 nephrectomized rats via the tryptophan-kynurenic acid-aryl hydrocarbon receptor pathway[J]. BMC Complement Med Ther, 2021, 21(1): 207.
[77]	金晓, 王文凤, 杨霓芝. 杨霓芝教授治疗慢性肾病药对应用经验撷菁[J]. 中国中西医结合肾病杂志, 2015, 16(9): 758-759. https://www.cnki.com.cn/Article/CJFDTOTAL-JXSB201509004.htm JIN X, WANG WF, YANG NZ. Professor Yang nizhi's experience in treating chronic nephropathy with drug pair[J]. Chin J Integr Tradit West Nephrol, 2015, 16(9): 758-759. https://www.cnki.com.cn/Article/CJFDTOTAL-JXSB201509004.htm
[78]	高婷婷, 罗广波, 方春平, 等. 基于肠道菌群研究黄芪治疗慢性肾炎[J]. 时珍国医国药, 2022, 33(1): 5-9. https://www.cnki.com.cn/Article/CJFDTOTAL-SZGY202201002.htm GAO TT, LUO GB, FANG CP, et al. Study on treatment of chronic nephritis with astragalus based on intestinal flora[J]. Lishizhen Med Mater Med Res, 2022, 33(1): 5-9. https://www.cnki.com.cn/Article/CJFDTOTAL-SZGY202201002.htm
[79]	麦文顶, 黄志敏, 唐宇, 等. 三七注射液对慢性肾衰竭大鼠肠道菌群多样性结构的影响研究[J]. 现代中西医结合杂志, 2022, 31(2): 147-152, 167. https://www.cnki.com.cn/Article/CJFDTOTAL-XDJH202202002.htm MAI WD, HUANG ZM, TANG Y, et al. Effects of Panax notoginseng injection on the diversity structure of intestinal flora in rats with chronic renal failure[J]. Mod J Integr Tradit Chin West Med, 2022, 31(2): 147-152, 167. https://www.cnki.com.cn/Article/CJFDTOTAL-XDJH202202002.htm
[80]	殷琳, 夏文睿, 黄国鑫, 等. 中药-肠道菌群互作与宿主自身代谢免疫稳态相关性的研究进展[J]. 中草药, 2022, 53(8): 2526-2538. https://www.cnki.com.cn/Article/CJFDTOTAL-ZCYO202208030.htm YIN L, XIA WR, HUANG GX, et al. Research progress on correlation between traditional Chinese medicine-gut microbiota and host's own metabolic immune homeostasis[J]. Chin Tradit Herb Drugs, 2022, 53(8): 2526-2538. https://www.cnki.com.cn/Article/CJFDTOTAL-ZCYO202208030.htm
[81]	欧阳文坤, 田春阳, 刘华熙, 等. 肾病Ⅱ号方对IgA肾病大鼠肠道菌群的调节作用研究[J]. 世界科学技术-中医药现代化, 2021, 23(4): 1274-1285. https://www.cnki.com.cn/Article/CJFDTOTAL-SJKX202104040.htm OUYANG WK, TIAN CY, LIU HX, et al. Study on the regulatory effect of shenbing Ⅱ formula on intestinal flora of rats with IgA nephropathy[J]. Mod Tradit Chin Med Mater Med World Sci Technol, 2021, 23(4): 1274-1285. https://www.cnki.com.cn/Article/CJFDTOTAL-SJKX202104040.htm
[82]	MING Y, CHENG SJ, LONG W, et al. The herbal formula granule prescription Mahuang Decoction ameliorated chronic kidney disease which was associated with restoration of dysbiosis of intestinal microbiota in rats[J]. Evid Based Complement Alternat Med, 2021, 2021: 4602612.
[83]	VANGAY P, WARD T, GERBER JS, et al. Antibiotics, pediatric dysbiosis, and disease[J]. Cell Host Microbe, 2015, 17(5): 553-564.
[84]	谢帆, 刘叶, 凌鑫隆, 等. 中医药治疗慢性肾病临床研究进展[J]. 新中医, 2019, 51(11): 23-26. https://www.cnki.com.cn/Article/CJFDTOTAL-REND201911007.htm XIE F, LIU Y, LING XL, et al. Clinical research progress of Chinese medicine in treating chronic kidney disease[J]. J N Chin Med, 2019, 51(11): 23-26. https://www.cnki.com.cn/Article/CJFDTOTAL-REND201911007.htm